Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
9Customers
2Debt Items
0Related Chains
Source-Backed Evidence Depth
BioCryst Pharmaceuticals, Inc. (BCRX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
14Total relationships
3Distinct source URLs
8High confidence
0.778Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
BioCryst Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
OMERS
OMERS
90%
In connection with the Stock Purchase Agreement, RPI and OMERS provided their written consent of the consummation of the sale of the Company’s European ORLADEYO business.
NEOPHARMED
NEOPHARMED
85%
Concurrent with the closing of the transaction on October 1, 2025, Neopharmed paid a $ 15,000 royalty release fee to RPI on behalf of the Company
BioCryst Pharmaceuticals, Inc. Customers
Ticker
Name
Confidence
Evidence
NEOPHARMED-GENTILI-S-P-A
NEOPHARMED-GENTILI-S-P-A
92%
the Company entered into a license agreement granting an Irish affiliate of Neopharmed Gentili S.p.A. exclusive rights to commercialize navenibart for hereditary angioedema in Europe
BIOCRYST-IRELAND
BIOCRYST-IRELAND
90%
The Company receives quarterly royalty payments from BioCryst Ireland equal to amounts owed under its Royalty Purchase Agreements with RPI and OMERS for the sale of ORLADEYO products in the Territory.
SPECIALTY-PHARMACY
SPECIALTY-PHARMACY
90%
Product revenue where the specialty pharmacy is considered the customer was approximately 93 % and 85 % of total product sales for the three months ended March 31, 2026 and 2025, respectively.
ASTRIA-THERAPEUTICS-INC
ASTRIA-THERAPEUTICS-INC
62%
. The transactions contemplated by each of the Royalty Purchase Agreements are referred to herein as the “Royalty Sales”. Under the Royalty Purchase Agreements, the Company has agreed to specified af…
ATHYRIUM-OPPORTUNITIES-III-CO
ATHYRIUM-OPPORTUNITIES-III-CO
62%
. The transactions contemplated by each of the Royalty Purchase Agreements are referred to herein as the “Royalty Sales”. Under the Royalty Purchase Agreements, the Company has agreed to specified af…
BIOPHARMA-CREDIT-PLC
BIOPHARMA-CREDIT-PLC
62%
. The transactions contemplated by each of the Royalty Purchase Agreements are referred to herein as the “Royalty Sales”. Under the Royalty Purchase Agreements, the Company has agreed to specified af…
BPCR-LIMITED
BPCR-LIMITED
62%
. The transactions contemplated by each of the Royalty Purchase Agreements are referred to herein as the “Royalty Sales”. Under the Royalty Purchase Agreements, the Company has agreed to specified af…
COMPANY-AXEL-MERGER-SUB-INC
COMPANY-AXEL-MERGER-SUB-INC
62%
uct, commercial revenue and product candidates. Further, the Company’s drug development activities are performed by a limited group of third-party vendors. If any of these vendors were unable to perf…
OCM-IP-HEALTHCARE-HOLDINGS-LIMITED
OCM-IP-HEALTHCARE-HOLDINGS-LIMITED
62%
ly resulting from interest rate changes. The Company does not have an intent to sell these investments, and it is more likely than not that the investments will be held until recovery of their amorti…
BioCryst Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
BCRX-DEBT
Debt stack $395.4M
90%
Market cache reports total debt of $395.4M.
BCRX-DEBT-8104
Warrants outstanding: 11765000
90%
xbrl warrant detail from xbrl 2020-12-31.
BioCryst Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for BioCryst Pharmaceuticals, Inc..
BioCryst Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
BCRX-OWNER-BLACKROCK-INC
BlackRock, Inc.
90%
13F overlay lists BlackRock, Inc. as top holder; 302 tracked holders.
BioCryst Pharmaceuticals, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
